Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely specify the specialty pharmacy(ies) selected as the designated partner(s).
Here are several LD deals that have been recently publicly confirmed subsequent to the approvals.
Rezlidhia HUB to be managed by AscellaHealth
December 13, 2022–(BUSINESS WIRE)–Optime Care, a member of the AscellaHealth Family of Companies, announced a contractual partnership with Rigel Pharmaceuticals, Inc., bringing its full suite patient support/HUB service capabilities to support Rezlidhia (olutasidenib), a recent FDA-approved treatment for adult patients with relapse or refractory acute myeloid leukemia (AML). Optime Care’s services for life sciences manufacturers include pre-commercialization and market access expertise, exclusive distribution partnerships, national medication fulfillment and high-touch patient support and HUB services for enhanced patient outcomes.
Rezlidhia now available at Biologics by McKesson
December 21, 2022 — McKesson Corporation recently announced that its independent specialty pharmacy, Biologics by McKesson, has been selected by Rigel Pharmaceuticals as one of two specialty pharmacies in a limited distribution network for Rezlidhia (olutasidenib). Rezlidhia is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
KRAZATI now available at Biologics by McKesson
Dec. 14, 2022 — Biologics by McKesson has been selected by Mirati Therapeutics as one of two specialty pharmacies in a limited distribution network for KRAZATI (adagrasib), indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation.
KRAZATI now available from Onco360
December 15, 2022–(BUSINESS WIRE)–Onco360 has been selected by Mirati Therapeutics to be a specialty pharmacy partner for KRAZATI (adagrasib) indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation.
HEMGENIX: Orsini Specialty Pharmacy Selected as a Limited Distribution Partner
Dec. 20, 2022 /PRNewswire/ — Orsini Specialty Pharmacy was selected by CSL Behring as a limited distribution partner for Hemgenix (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy option for hemophilia B. Hemgenix is indicated for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy or have current or historical life-threatening hemorrhage or have repeated, serious spontaneous bleeding episodes.
